Home > Insider Trading > Filing (0000899243-19-030135)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1266625	Ralf Rosskamp	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-12-26	20,000	$2.91	23,564	No	4	M	Direct
Common Stock	Disposition	2019-12-26	20,000	$22.69	3,564	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2019-12-26	20,000	$0.00	20,000	$2.91

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
230,000		2027-06-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.48 to $23.13, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of to Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
The option vested 25% on the first-year anniversary of the vesting start date of June 15, 2017 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.